<DOC>
	<DOC>NCT00726427</DOC>
	<brief_summary>The purpose of this study is to assess safety and tolerability of AZD1656 after single ascending oral doses in healthy male subjects</brief_summary>
	<brief_title>A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Provision of informed consent Clinically normal physical findings and laboratory values as judged by the investigator including negative test of Hepatitis B surface antigen, antibodies to HIV virus and antibodies to hepatitis C virus. Clinically significant illness or clinically relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the Investigational Product History of psychiatric or somatic disease/condition that may interfere with the objectives of the study, as judged by the investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>AZD1656</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>